His Majesty King Charles III Extends Congratulations to King Norodom Sihamoni on Cambodia’s Independence Day | U.S. Secretary of State Antony Blinken Extends Congratulations to Cambodia on Independence Day | Cambodia Welcomes Unprecedented Dolphin Birth Rate in Last Four Years | Techo Santepheap Road at Angkol Beach Officially Launched, Enhancing Tourism and Connectivity in Kep | Kampong Phluk Ecotourism Community: A Potential Eco-Tourism Destination in Siem Reap | Typhoons Yinxing and Toraji Impact Northeast Monsoon Regime | Senate Standing Committee Sends Draft Laws for Expert Review | Three Bodhi Trees Planted at Vipassana Dhamma Center in Siem Reap |

People Can Now Buy Up to 10 Doses of Molnupiravir Covid-19 Treatment Drug

PHNOM PENH: The Working Group for the Management, Distribution and Supply of Strategic Medicines for Combating Covid-19 of the Ministry of Health has decided to allow citizens to purchase up to 10 doses, or boxes, of the Covid-19 treatment medication, Molnupiravir, at US $50 per dose.

In a statement issued by the National Commission for Disease Control and Prevention on Friday, 11 March, the working group decided that the new terms of sale for Molnupiravir will start on Monday, 14 March, at the office of the Ministry of Posts and Telecommunications and Cambodia Post Branch.

In addition to allowing citizens to buy up to 10 doses, the team has also decided to allow private hospitals, clinics, pharmacies and sub-pharmacies to purchase up to 100 doses, but these institutions must have a valid business license and are unable to resell the medicine for more than US $60 per box. Additionally, the treatment drugs can be re-ordered at least once a week.

The statement also warned that the working group will cooperate with the competent authorities to take strict action against any private hospitals, clinics, pharmacies, sub-pharmacies or resellers who exceed the stated maximum resell price of US $60.

Molnupiravir is a product of the pharmaceutical company Merck in the United States, developed as a treatment drug for adults with mild to moderate Covid-19. The drug has been certified by the Ministry of Health as safe and highly effective for the treatment of Covid-19 and was first approved for use on 3 November 2021.


Related News